Abstracts Archive - Page 2334 of 2425 - ACR Meeting Abstracts

Abstract Number: 1330 • 2012 ACR/ARHP Annual Meeting
High Body Mass Index Is Associated with Decreased Response to Initial Combination Therapy in Recent Onset RA Patients
Marianne van den Broek¹, L. Heimans², S. le Cessie³, B. Siegerink³, H.K Ronday⁴, K.H. Han⁵, P.J.S.M. Kerstens⁶, T.W.J. Huizinga², W.F. Lems⁷ and C.F. Allaart², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medical statistics and Epidemiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, MCRZ hospital, Rotterdam, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU University medical center, Amsterdam, Netherlands
High BMI is associated with decreased response to initial combination therapy in recent onset RA patients Background/Purpose: A diminished response to combination treatment with a fixed…
Abstract Number: 1331 • 2012 ACR/ARHP Annual Meeting
Once Daily High Dose Regimens of GLPG0634 in Healthy Volunteers Are Safe and Provide Continuous Inhibition of JAK1 but Not JAK2
Florence Namour¹, René Galien¹, Lien Gheyle², Frédéric Vanhoutte³, Béatrice Vayssière¹, Annegret Van der Aa³, Bart Smets³ and Gerben van 't Klooster³, ¹Galapagos SASU, Romainville, France, ²SGS Clinical Pharmacology Unit, Antwerp, Belgium, ³Galapagos NV, Mechelen, Belgium
Background/Purpose: GLPG0634 is an orally-available, selective inhibitor of Janus kinase 1 (JAK1) with an IC50 of 0.6 μM and a 30-fold selectivity over JAK2 in…
Abstract Number: 1332 • 2012 ACR/ARHP Annual Meeting
The Incidence of Exacerbation of Pre-Existing Interstitial Lung Disease (ILD) Is Higher in TNF Blockers Than in Non-TNF Blockers in RA
Tamao Nakashita¹, Shinji Motojima², Natsuki Fujio² and Akira Jibatake³, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa City, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ³Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: Exacerbation of interstitial lung disease (ILD) is a problem when biologics are administrated in patients with RA, and not a few fatal cases have…
Abstract Number: 1333 • 2012 ACR/ARHP Annual Meeting
The Predictive Value of CD64 Counts for Infectious Disease in Patients Treated with Tocilizumab On the Infectious Disease Risk Management Cohort (ACT4U-study)
Atsushi Ihata¹, Hiroyuki Hagiyama², Shouhei Nagaoka³, Junichi Obata⁴, Kiyomitsu Miyachi⁵, Hidehiro Yamada⁶, Shunsei Hirohata⁷, Norihiko Koido⁸, Masaomi Yamasaki⁹, Kenichi Miyagi¹⁰, Shigeru Ohno¹¹, Daiga Kishimoto¹, Reikou Watanabe¹, Takeaki Uehara¹², Kaoru Takase¹, Maasa Hama¹, Ryusuke Yoshimi¹, Atsuhisa Ueda¹, Mitsuhiro Takeno¹ and Yoshiaki Ishigatsubo¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Rheumatology, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, ³Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, ⁴Hikarichuo Clinic, Kawasaki, Japan, ⁵Keigu Clinic, Kawasaki, Japan, ⁶Internal Medicine, St. Marianna University, Kawasaki, Japan, ⁷Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ⁸Kawasaki Rheumatism & Internal Medecine Clinic, Kawasaki, ⁹Internal Medicine, St Marianna University, Yokohama City Seibu Hospital, Yokohama, Japan, ¹⁰Miyagi Naika Clinic, Yokohama, ¹¹Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ¹²Department of Rheumatology, Chigasaki Municipal Hospital, Chigasaki, Japan
Background/Purpose: An administration of tocilizumab (TCZ) rapidly suppresses inflammatory markers such as CRP and ESR, which makes the diagnosis of infection difficult. There is a…
Abstract Number: 1334 • 2012 ACR/ARHP Annual Meeting
Intra-Articular Etanercept Treatment in Inflammatory Arthritis: A Randomized Double-Blind Placebo-Controlled Trial
Caroline J. Aalbers¹, Danielle M. Gerlag², Koen Vos¹, Gertjan Wolbink³, R. Landewe¹ and Paul P. Tak⁴, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: The use of intra-articular (IA) corticosteroid injections has been widely accepted as a therapy to control local inflammation. Studies on the use of IA…
Abstract Number: 1335 • 2012 ACR/ARHP Annual Meeting
Remission Induction in Early Active Rheumatoid Arthritis: Comparison of Tocilizumab Versus Methotrexate Monotherapy
Patrick Durez¹, Geneviève Depresseux², Marie Avaux², Adrien Nzeusseu Toukap³, Bernard Lauwerys³, Laurent Meric de Bellefon², Maria S. Stoenoiu² and Frédéric A. Houssiau⁴, ¹Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, ³Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ⁴Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Tocilizumab (TCZ), as monotherapy and in combination with methotrexate (MTX), has been shown to be efficacious for rheumatoid arthritis patients with insufficient response to…
Abstract Number: 1296 • 2012 ACR/ARHP Annual Meeting
An Interim Analysis of the Efficacy of Abatacept in Japanese Biologics-naïve Rheumatoid Arthritis Patients (results from ABROAD study): Comparison of CRP and MMP-3 Level After Treatment with Abatacept Versus Anti-TNF Agents
Masahiro Sekiguchi¹, Kiyoshi Matsui¹, Masayasu Kitano¹, Mitsuo Namiki¹, Koichiro Ohmura², Takao Fujii³, Hideko Nakahara⁴, Keiji Maeda⁴, Hideo Hashimoto⁵, Takanori Kuroiwa⁶, Kenji Miki⁷, Masanori Funauchi⁸, Kazuhiro Hatta⁹, Kenshi Higami¹⁰, Shunzo Namiuchi¹¹, Ichiro Yoshii¹², Teruyuki Nakatani¹³, Takashi Ikawa¹⁴, Takaji Matsutani¹⁵, Kosaku Murakami¹⁶, Satoshi Morita¹⁷, Yutaka Kawahito¹⁸, Norihiro Nishimoto¹⁵, Tsuneyo Mimori¹⁹ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Department of Rheumatology & Clin Immunology, Kyoto University, Kyoto, Japan, ³Dept of Rheum/Clinical Immun, Graduate School of Medicine,, Kyoto University, Kyoto, Japan, ⁴Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁵Dept of Orthopedic Surgery, Rinku Hashimoto Rheumatology Orthopaedics, Osaka, Japan, ⁶Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ⁷Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁸Division of Hematology and Rheumatology, Department of Medicine, Kinki University Faculty of Medicine, Osaka, Japan, ⁹Department of Internal Medicine, Tenri Yorozu Sodansyo Hospital, Nara, ¹⁰Department of Rheumatology, Higami Hospital, Nara, Japan, ¹¹Department of Rheumatology, Saiseikai Nakatsu Hospital, Osaka, Japan, ¹²Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹³Department of Orthopaedic Surgery, Kishiwada City Hospital, Osaka, Japan, ¹⁴Osaka Rehabilitation Hospital, Hannan, Japan, ¹⁵Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki, Japan, ¹⁶Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, Osaka, Japan, ¹⁷Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁸Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ¹⁹Dept of Rheum & Clinical Immun, Kyoto University, Kyoto, Japan
Background/Purpose: Abatacept (ABA) is a recombinant fusion protein consisting of the extracellular domain of human CTLA-4, binding to CD80/86 on antigen presenting cells (APCs) and…
Abstract Number: 1297 • 2012 ACR/ARHP Annual Meeting
Tofacitinib and Adalimumab Achieve Similar Rates of Low Disease Activity in Rheumatoid Arthritis — Lack of Improvement in Disease Activity Score by 3 Months Predicts Low Likelihood of Low Disease Activity At 1 Year
Ronald F. van Vollenhoven¹, Sriram Krishnaswami², Birgitta Benda³, David Gruben⁴, Bethanie Wilkinson⁴, Charles A. Mebus⁴, Samuel H. Zwillich² and John Bradley², ¹Karolinska Institute, Stockholm, Sweden, ²Pfizer Inc, Groton, CT, ³Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This post-hoc analysis of the…
Abstract Number: 1298 • 2012 ACR/ARHP Annual Meeting
Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach
Shunichi Kumagai¹, Yoshiaki Hagiwara², Yoshihide Ichise¹, Sho Sendo³, Nobuhiko Okada¹, Jun Saegusa⁴ and Goh Tsuji⁵, ¹Center of rheumatic diseases, Shinko hospital, Kobe, Japan, ²Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ³Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, ⁴Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: Salazosulfapyridine (SASP) is acetylated in liver by N-acetyltransferase2 (NAT2) in the track of metabolism. Previous studies have shown that genotyping of NAT2 is adequate…
Abstract Number: 1299 • 2012 ACR/ARHP Annual Meeting
Rituximab Versus Abatacept in Rheumatoid Arthritis Patients with an Inadequate Response to Prior Biologic Therapy: A Retrospective, Single-Center Study
Edward Keystone¹, Juan Xiong², Deborah Weber³ and Ye Sun⁴, ¹The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, Toronto, ON, Canada, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Patients with RA who experience an inadequate response to TNF inhibitor (TNFi) therapy (TNF-IR) may be successfully treated using an alternative TNFi or a…
Abstract Number: 1300 • 2012 ACR/ARHP Annual Meeting
Characteristics Associated with Biologic Initiation As Monotherapy Versus Combination Therapy in Patients with Rheumatoid Arthritis (RA) in a US Registry Population
Dimitrios A. Pappas¹, George W. Reed², Katherine C. Saunders³, Ani John⁴, Ashwini Shewede⁴, Jenny Devenport⁵, Jeffrey D. Greenberg⁶ and Joel M. Kremer⁷, ¹Columbia University, New York, NY, ²University of Massachusetts Medical School, Worcester, MA, ³Corrona, LLC., Southborough, MA, ⁴Genentech Inc., South San Francisco, CA, ⁵Genentech, South San Francisco, CA, ⁶Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Approximately one-third of RA patients were prescribed biologic (Bio) monotherapy (MT) i.e. without concomitant disease-modifying anti-rheumatic drugs (DMARD) (Yazici et al., 2008). The purpose…
Abstract Number: 1301 • 2012 ACR/ARHP Annual Meeting
Predictors of Significant Disease Activity Score-28 (Using C-reactive protein) Remission Achieved with Intravenous Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
Clifton O. Bingham III¹, Michael Weinblatt², Alan Mendelsohn³, Lilianne Kim⁴, Michael Mack⁵, Jiandong Lu⁵, Daniel Baker³ and Rene Westhovens⁶, ¹Department of Medicine, Johns Hopkins University, Baltimore, MD, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁶Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Predictors of Significant Disease Activity Score-28 (Using C-reactive protein) Remission Achieved with Intravenous Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of…
Abstract Number: 1302 • 2012 ACR/ARHP Annual Meeting
Early Neutropenia Is Associated with Clinical Response in Patients Receiving Tocilizumab in Rheumatoid Arthritis
Marie Kostine¹, Thomas Barnetche², Elodie Ardouin³, Marlene Joly⁴, Emilie Rabois⁵, Baptiste Glace Sr.⁶, Delphine Nigon⁷, Thierry Schaeverbeke⁸ and Christophe Richez⁹, ¹Rheumatology, CHU Pellegrin, Bordeaux, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, Limoges University Hospital, Limoges, France, ⁴Rheumatology, Montpellier University Hospital, Montpellier, France, ⁵Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁶Rheumatology, Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, ⁷CHU Purpan, Toulouse, France, ⁸Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁹Hôpital Pellegrin and Université Victor Segalen Bordeaux, France
Background/Purpose: A reduction in peripheral blood neutrophils count is usually observed with the anti-interleukin (IL) 6 receptor antibody tocilizumab. This often appears few days after…
Abstract Number: 1303 • 2012 ACR/ARHP Annual Meeting
Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone
Edward Keystone¹, Ferdinand C. Breedveld², Désirée van der Heijde³, Ronald F. van Vollenhoven⁴, Stefan Florentinus⁵, Freddy Faccin⁶, Shufang Liu⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹University of Toronto, Professor of Medicine, Toronto, ON, Canada, ²Dept of Rheumatology C1R, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Karolinska Institute, Stockholm, Sweden, ⁵AbbVie, Rungis, France, ⁶Abbott, Abbott Park, IL, ⁷Immunology Development, Abbott, Abbott Park, IL, ⁸Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁹UCSD School of Medicine, La Jolla, CA
Background/Purpose: Effective treatment of rheumatoid arthritis (RA) patients (pts) aims to suppress inflammation, preserve physical function, and prevent structural damage, which together represent the hallmarks…
Abstract Number: 1304 • 2012 ACR/ARHP Annual Meeting
Long-Term Use of Adalimumab As Monotherapy Following Attainment of Low Disease Activity with Adalimumab Plus Methotrexate
Edward Keystone¹, Ferdinand C. Breedveld², Hartmut Kupper³, Shufang Liu⁴ and Stefan Florentinus⁵, ¹University of Toronto, Professor of Medicine, Toronto, ON, Canada, ²Leiden University Medical Center, Leiden, Netherlands, ³Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁴Immunology Development, Abbott, Abbott Park, IL, ⁵AbbVie, Rungis, France
Background/Purpose: There has been increased interest in understanding whether biologics can be safely withdrawn from patients (pts) receiving combination therapy with MTX once a clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].